<DOC>
	<DOCNO>NCT02637960</DOCNO>
	<brief_summary>This study investigate efficacy safety fedovapagon treatment nocturia men BPH .</brief_summary>
	<brief_title>Efficacy Study Fedovapagon Nocturia Men With Benign Prostatic Hyperplasia ( BPH )</brief_title>
	<detailed_description>Fedovapagon selective vasopressin V2 receptor ( V2R ) agonist antidiuretic effect stimulation V2 receptor kidney develop treatment nocturia . Nocturia , define complaint individual wake night one time void , common condition show age-dependent increase prevalence severity ( number nocturnal void ) . It significant detrimental impact quality life patient benign prostatic hyperplasia ( BPH ) . The purpose study determine efficacy safety fedovapagon treatment nocturia BPH .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Nocturia</mesh_term>
	<criteria>Adult male â‰¥18 year [ upper limit ] Benign prostatic hyperplasia Persistent nocturia despite previous lifestyle modification advice include appropriate fluid management Serum sodium lower limit normal prior randomization Provide sign date informed consent studyspecific procedure conduct . Able comply requirement study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>VA106483 , fedovapagon , BPH , nocturia , EQUINOC</keyword>
</DOC>